Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel ...

1. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017;390:2769–2778.
crossref pmid
2. Can G, Posul E, Yilmaz B, et al. Epidemiologic features of inflammatory bowel disease in Western Blacksea region of Turkey for the last 10 years: retrospective cohort study. Korean J Intern Med 2019;34:519–529.
crossref pmid pmc pdf
3. Kaibullayeva J, Ualiyeva A, Oshibayeva A, Dushpanova A, Marshall JK. Prevalence and patient awareness of inflammatory bowel disease in Kazakhstan: a cross-sectional study. Intest Res 2020;18:430–437.
crossref pmid pmc pdf
4. Sood A, Kaur K, Mahajan R, et al. Colitis and Crohn’s Foundation (India): a first nationwide inflammatory bowel disease registry. Intest Res 2021;19:206–216.
crossref pmid pmc pdf
5. Mizoguchi E, Low D, Ezaki Y, Okada T. Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models. Intest Res 2020;18:151–167.
crossref pmid pmc pdf
6. Ardali R, Kazemipour N, Nazifi S, Bagheri Lankarani K, Razeghian Jahromi I, Sepehrimanesh M. Pathophysiological role of Atg5 in human ulcerative colitis. Intest Res 2020;18:421–429.
crossref pmid pmc pdf
7. Vulliemoz M, Brand S, Juillerat P, et al. TNF-alpha blockers in inflammatory bowel diseases: practical recommendations and a user’s guide: an update. Digestion 2020;101:Suppl 1. 16–26.
crossref pmid pdf
8. Sokol H, Seksik P, Cosnes J. Complications and surgery in the inflammatory bowel diseases biological era. Curr Opin Gastroenterol 2014;30:378–384.
crossref pmid
9. Im JP, Ye BD, Kim YS, Kim JS. Changing treatment paradigms for the management of inflammatory bowel disease. Korean J Intern Med 2018;33:28–35.
crossref pmid pmc pdf
10. Jung YS, Han M, Park S, Cheon JH. Impact of early anti-TNF use on clinical outcomes in Crohn’s disease: a nationwide population-based study. Korean J Intern Med 2020;35:1104–1113.
crossref pmid pmc pdf
11. Roda G, Jharap B, Neeraj N, Colombel JF. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol 2016;7:e135.
crossref pmid pmc pdf
12. Hong SW, Park J, Yoon H, et al. Comparison of loss of response between anti-tumor necrosis factor alone and combined use with immunomodulators in patients with inflammatory bowel disease. Korean J Intern Med 2021;36(Suppl 1):S9–S17.
crossref pmid pmc pdf
13. Choi SJ, Oh JS, Hong S, Lee CK, Yoo B, Kim YG. Liver enzyme elevation in patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors: a single-center historical cohort study. Korean J Intern Med 2020;35:723–731.
crossref pmid pmc pdf
14. Lee HS, Park SK, Park DI. Novel treatments for inflammatory bowel disease. Korean J Intern Med 2018;33:20–27.
crossref pmid pmc pdf
15. Samanen JC. Similarities and differences in the discovery and use of biopharmaceuticals and small molecule chemotherapeutics. In: Ganellin R, Roberts S, Jefferis R, eds. Introduction to Biological and Small Molecule Drug Research and Development. Oxford (UK): Elsevier, 2013;161–203.
crossref
16. Na SY, Moon W. Perspectives on current and novel treatments for inflammatory bowel disease. Gut Liver 2019;13:604–616.
crossref pmid pmc
17. Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology 2019;156:1508–1524.
crossref pmid
18. Jovani M, Danese S. Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells. Curr Drug Targets 2013;14:1433–1443.
crossref pmid
19. Mullershausen F, Zecri F, Cetin C, Billich A, Guerini D, Seuwen K. Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol 2009;5:428–434.
crossref pmid pdf
20. O’Sullivan C, Dev KK. The structure and function of the S1P1 receptor. Trends Pharmacol Sci 2013;34:401–412.
crossref pmid
21. Sanchez T, Hla T. Structural and functional characteristics of S1P receptors. J Cell Biochem 2004;92:913–922.
crossref pmid
22. Lobaton T, Vermeire S, Van Assche G, Rutgeerts P. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2014;39:579–594.
crossref pmid
23. Scott FL, Clemons B, Brooks J, et al. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity. Br J Pharmacol 2016;173:1778–1792.
crossref pmid pmc
24. Sandborn WJ, Feagan BG, Wolf DC, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med 2016;374:1754–1762.
crossref pmid
25. Sandborn WJ, Feagan BG, Hanauer S, et al. Long-term efficacy and safety of ozanimod in moderately to severely active ulcerative colitis: results from the open-label extension of the randomized, phase 2 TOUCHSTONE Study. J Crohns Colitis 2021;15:1120–1129.
crossref pmid pmc pdf
26. Sandborn WJ, Feagan BG, D’Haens G, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2021;385:1280–1291.
crossref pmid
27. Brossard P, Derendorf H, Xu J, Maatouk H, Halabi A, Dingemanse J. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-inhuman study. Br J Clin Pharmacol 2013;76:888–896.
crossref pmid pmc
28. Feagan BG, Sandborn WJ, Danese S, et al. Ozanimod induction therapy for patients with moderate to severe Crohn’s disease: a single-arm, phase 2, prospective observer-blinded endpoint study. Lancet Gastroenterol Hepatol 2020;5:819–828.
crossref pmid
29. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 2005;353:1912–1925.
crossref pmid
30. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology 2007;132:1672–1683.
crossref pmid
31. del Pilar Martin M, Cravens PD, Winger R, et al. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol 2008;65:1596–1603.
crossref pmid
32. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369–374.
crossref pmid
33. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375–381.
crossref pmid
34. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699–710.
crossref pmid
35. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013;369:711–721.
crossref pmid
36. Ooi CJ, Hilmi IN, Kim HJ, et al. Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study. Intest Res 2021;19:71–82.
crossref pmid pmc pdf
37. Banerjee R, Chuah SW, Hilmi IN, et al. Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study. Intest Res 2021;19:83–94.
crossref pmid pmc pdf
38. Okamoto H, Dirks NL, Rosario M, Hori T, Hibi T. Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease. Intest Res 2021;19:95–105.
crossref pmid pmc pdf
39. Feagan BG, Rubin DT, Danese S, et al. Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists. Clin Gastroenterol Hepatol 2017;15:229–239.
crossref pmid
40. Sands BE, Sandborn WJ, Van Assche G, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease in patients naive to or who have failed tumor necrosis factor antagonist therapy. Inflamm Bowel Dis 2017;23:97–106.
pmid
41. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014;147:618–627.
crossref pmid
42. Kim J, Yoon H, Kim N, et al. Clinical outcomes and response predictors of vedolizumab induction treatment for Korean patients with inflammatory bowel diseases who failed anti-TNF therapy: a KASID prospective multicenter cohort study. Inflamm Bowel Dis 2021;27:1931–1941.
crossref pmid pdf
43. Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med 2019;381:1215–1226.
crossref pmid
44. Feagan BG, Lasch K, Lissoos T, et al. Rapid response to vedolizumab therapy in biologic-naive patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2019;17:130–138.
crossref pmid
45. Schwartz DA, Peyrin-Biroulet L, Lasch K, Adsul S, Danese S. Efficacy and safety of 2 vedolizumab intravenous regimens for perianal fistulizing Crohn’s disease: ENTERPRISE Study. Clin Gastroenterol Hepatol 2022;20:1059–1067.
crossref pmid
46. Ayoub F, Odenwald M, Micic D, et al. Vedolizumab for perianal fistulizing Crohn’s disease: systematic review and meta-analysis. Intest Res 2022;20:240–250.
crossref pmid pmc pdf
47. Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 2017;66:839–851.
crossref pmid pmc
48. Milch C, Wyant T, Xu J, et al. Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype. J Neuroimmunol 2013;264:123–126.
crossref pmid
49. Loftus EV Jr, Feagan BG, Panaccione R, et al. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther 2020;52:1353–1365.
crossref pmid pmc pdf
50. Na SY. Treatment of inflammatory bowel disease in elderly patients: what are different and what should we know? Korean J Gastroenterol 2021;77:231–240.
crossref pmid
51. Poylin VY, Serrato JC, Pastrana Del Valle J, Feuerstein JD. Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study. Intest Res 2022;20:72–77.
crossref pmid pmc pdf
52. Benson JM, Peritt D, Scallon BJ, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs 2011;3:535–545.
crossref pmid pmc
53. Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 2003;3:900–911.
crossref pmid pdf
54. Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol 2007;178:2623–2629.
crossref pmid
55. Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009;228:273–287.
crossref pmid pmc
56. Wittig BM. Drug evaluation: CNTO-1275, a mAb against IL-12/IL-23p40 for the potential treatment of inflammatory diseases. Curr Opin Investig Drugs 2007;8:947–954.
pmid
57. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2016;375:1946–1960.
pmid
58. Hibi T, Imai Y, Murata Y, Matsushima N, Zheng R, Gasink C. Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn’s disease: a subpopulation analysis of phase 3 induction and maintenance studies. Intest Res 2017;15:475–486.
crossref pmid pmc pdf
59. Saman S, Goetz M, Wendler J, Malek NP, Wehkamp J, Klag T. Ustekinumab is effective in biological refractory Crohn’s disease patients-regardless of approval study selection criteria. Intest Res 2019;17:340–348.
crossref pmid pmc pdf
60. Cohen A, Ahmed N, Sant’Anna A. Ustekinumab for the treatment of refractory pediatric Crohn’s disease: a single-center experience. Intest Res 2021;19:217–224.
crossref pmid pmc pdf
61. Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2019;381:1201–1214.
crossref pmid
62. Hisamatsu T, Kim HJ, Motoya S, et al. Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI). Intest Res 2021;19:386–397.
crossref pmid pmc pdf
63. Sandborn WJ, Rutgeerts P, Gasink C, et al. Long-term efficacy and safety of ustekinumab for Crohn’s disease through the second year of therapy. Aliment Pharmacol Ther 2018;48:65–77.
crossref pmid pmc pdf
64. Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for ustekinumab and other Psoriasis Treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol 2015;14:706–714.
pmid
65. Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol 2016;30:1148–1158.
crossref pmid pmc pdf
66. Olivera P, Danese S, Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut 2017;66:199–209.
crossref pmid
67. Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017;376:1723–1736.
crossref pmid
68. Sandborn WJ, Peyrin-Biroulet L, Quirk D, et al. Efficacy and safety of extended induction with tofacitinib for the treatment of ulcerative colitis. Clin Gastroenterol Hepatol 2022;20:1821–1830.
crossref pmid
69. Motoya S, Watanabe M, Kim HJ, et al. Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies. Intest Res 2018;16:233–245.
crossref pmid pmc pdf
70. Panes J, Sandborn WJ, Schreiber S, et al. Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials. Gut 2017;66:1049–1059.
crossref pmid pmc
71. Hanauer S, Panaccione R, Danese S, et al. Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis. Clin Gastroenterol Hepatol 2019;17:139–147.
crossref pmid
72. Uzzan M, Bresteau C, Laharie D, et al. Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: a GETAID cohort. Aliment Pharmacol Ther 2021;54:312–319.
crossref pmid pdf
73. Shimizu H, Fujii T, Hibiya S, et al. Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis. Intest Res 2021;19:115–118.
crossref pmid pmc pdf
74. Sandborn WJ, Panes J, D’Haens GR, et al. Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from Global Clinical Trials. Clin Gastroenterol Hepatol 2019;17:1541–1550.
crossref pmid
75. Desai RJ, Pawar A, Khosrow-Khavar F, Weinblatt ME, Kim SC. Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study. Rheumatology (Oxford) 2021;61:121–130.
crossref pmid pdf
76. Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 2022;386:316–326.
crossref pmid
78. Sandborn WJ, Ghosh S, Panes J, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology 2020;158:2139–2149.
crossref pmid
79. Sandborn WJ, Feagan BG, Loftus EV Jr, et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease. Gastroenterology 2020;158:2123–2138.
crossref pmid
80. D’Haens G, Panes J, Louis E, et al. Upadacitinib was efficacious and well-tolerated over 30 months in patients with Crohn’s disease in the CELEST Extension Study. Clin Gastroenterol Hepatol 2021;Dec. 27. [Epub]. https://doi.org/10.1016/j.cgh.2021.12.030 .
crossref pmid
81. Sands BE, Chen J, Feagan BG, et al. Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn’s disease: a phase 2a study. Gastroenterology 2017;153:77–86.
crossref pmid
82. Feagan BG, Sandborn WJ, D’Haens G, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 2017;389:1699–1709.
crossref pmid
83. Sandborn WJ, Ferrante M, Bhandari BR, et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis. Gastroenterology 2020;158:537–549.
crossref pmid
84. Sandborn WJ, Ferrante M, Bhandari BR, et al. Efficacy and safety of continued treatment with mirikizumab in a phase 2 trial of patients with ulcerative colitis. Clin Gastroenterol Hepatol 2022;20:105–115.
crossref pmid
85. Sands BE, Peyrin-Biroulet L, Kierkus J, et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn’s disease. Gastroenterology 2022;162:495–508.
crossref pmid
86. Feagan BG, Danese S, Loftus EV Jr, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet 2021;397:2372–2384.
crossref pmid
87. Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double- blind, randomised, placebo-controlled trial. Lancet 2017;389:266–275.
crossref pmid
88. D’Amico F, Magro F, Peyrin-Biroulet L, Danese S. Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis. J Crohns Colitis 2022;16:835–844.
crossref pmid pmc pdf
89. Tang MT, Keir ME, Erickson R, et al. Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease. Aliment Pharmacol Ther 2018;47:1440–1452.
crossref pmid pmc pdf
90. Peyrin-Biroulet L, Hart A, Bossuyt P, et al. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol Hepatol 2022;7:128–140.
pmid
91. Vermeire S, Lakatos PL, Ritter T, et al. Etrolizumab for maintenance therapy in patients with moderately

留言 (0)

沒有登入
gif